IMAP’s Conflict of Interest Policy Database houses policies on clinical conflict of interest from the nation's academic medical centers (AMCs). Used in conjunction with our best practice guides, the database serves as an educational resource for schools seeking to strengthen their policies.
The policies in the database have been collected through three methods. First, IMAP directly contacted AMCs to request copies of their policies for inclusion in the database. Second, to supplement these findings, IMAP’s research team searched schools’ websites for relevant polices. Third, IMAP updates the database as AMCs make new policies publicly available. Schools wishing to update their entries may contact IMAP atCCOIemail@example.com.
The database enables users to search for a particular school's policy or to search within specific policy areas (e.g., policies on gifts from industry, policies on commercial support for continuing medical education). Users may search for policies using multiple criteria. Links to schools’ current policies are included within the entries.
Web-Based Curriculum: Promoting Change at AMCs and other healthcare organizations
IMAP's Web-Based Curriculum offers a comprehensive guide to the issues surrounding conflict of interest in clinical care, professionalism in medicine, and management of physicians’ relationships with industry. The materials provided here are relevant to anyone interested in understanding and/or teaching conflict of interest in medicine. The curriculum is an especially valuable resource for medical professionals in leadership positions at healthcare organizations, academic medical faculty, compliance officers, and any other agents who are attempting to bring about policy change.
Best Practices Toolkits
IMAP offers Best Practices for managing interactions between physicians and industry at AMCs. These recommendations were developed through intensive case studies of AMCs with innovative and effective policies for controlling conflict of interest.
These materials were made possible by a grant from the Oregon Department of Justice’s Prescriber and Consumer Education Grant Program
which is funded by the multi-state settlement of consumer fraud claims regarding the marketing of the prescription drug Neurontin.